Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma

NCT01211262 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT01211262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma
Lead sponsor
Immunocore Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2010
Completion date
February 16, 2017
Enrollment
84 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma